Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 7/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833029 | 0.88 | LIPG (0.45) | LPLLIPGROCK1IRAK4PRMT5 | |
| SCHEMBL3475430 | 0.87 | P2RX4 (0.40) | HIF1ALPLLIPGROCK1IRAK4 | |
| SCHEMBL20114066 | 0.86 | LIPG (0.55) | LPLLIPGROCK1IRAK4 | |
| SCHEMBL12620488 | 0.84 | LIPG (0.40) | HIF1ALPLLIPG | |
| SCHEMBL18544780 | 0.84 | LIPG (0.49) | LPLLIPGROCK1IRAK4PRMT5 | |
| SCHEMBL29662174 | 0.84 | LPL (0.51) | LPLLIPG | |
| SCHEMBL18222125 | 0.84 | LPL (0.51) | LPLLIPG | |
| SCHEMBL20114087 | 0.83 | LPL (0.39) | LPLLIPGROCK1IRAK4 | |
| SCHEMBL20114070 | 0.82 | LPL (0.50) | LPLLIPGROCK1IRAK4PRMT5 | |
| SCHEMBL3476592 | 0.82 | HDAC6 (0.38) | HIF1ALPLLIPGROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10886477-B2 | Iridium complex and organic electroluminescence device using the same | UDC IRELAND LIMITED (IE) | 2021-01-05 | — | — | US | disclosed |
| US-20190296251-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190296251-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IMPA1, LAGE3, OCIAD1 | HIF1A 4672/4885LPL 2650/4885LIPG 2700/4885 |
| US-10886477-B2 | Iridium complex and organic electroluminescence device using the same | IMPA1, LAGE3, OCIAD1 | HIF1A 4672/4885LPL 2650/4885LIPG 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.